This secondary analysis of the STEP-HFpEF (Semaglutide Treatment Effect in People with Obesity and HFpEF) program reveals that semaglutide provides benefits for men and women that do not track directly with weight loss, suggesting the drug may also have weight-loss independent effects on the cardiovascular system
It was approved to treat obesity in 2023 and moderate to severe sleep apnea in adults with obesity in 2024
This receptor-specific selectivity is the mechanistic basis for its pharmacological advantages over GHRP-6, which more closely mimics ghrelins full effect profile
So thats kind of not practical
Currently, there is no established causal link between tirzepatide and erectile dysfunction based on clinical trial data, post-marketing surveillance, or the MHRA-approved Summary of Product Characteristics
Semaglutide works by increasing insulin levels in the body, reducing the amount of sugar released into the blood and slowing digestion all of which can help with blood sugar management (diabetes) and weight loss
